RxDoctor Payments Data

Carla Krebs, MD

Ophthalmology · Fairview Park, OHNPI 1487659066

Payments from drug & device makers

$3,491in general payments, 2019–2025

Across 164 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$699
  • AbbVie$424
  • Ivantis, Inc$378
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$275
  • Biotissue Holdings Inc.$274
  • Sun Pharmaceutical Industries Inc.$250
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,45199%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,491 in reported general payments places this provider in the 75th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$297,576
Medicare patients
747
Services billed
3,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine27$33,242
VyzultaLatanoprostene Bunod49$23,467
ProlensaBromfenac Sodium51$15,644
Bromfenac Sodium80$14,018
Cyclosporine16$12,290
Prednisolone Acetate254$11,818
Latanoprost734$8,778
LumiganBimatoprost18$7,580
Travoprost34$4,479
MoxifloxacinMoxifloxacin Hcl207$4,208
Timolol Maleate113$3,058
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat155$2,276
Brimonidine Tartrate131$1,680
Ketorolac Tromethamine84$1,589
Dorzolamide Hcl38$676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$424$40,82245 claims
Bausch & Lomb Americas Inc.Vyzulta$48$23,46749 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$275$15,64451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Fairview Park

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →